# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹1,718 Cr** 9M (+10% YoY) * **EBITDA Margin:** **13%** adjusted (ex-growth investments) * **Debt & Cash:** **₹800 Cr** debt · **₹90–100 Cr** cash * **GST Receivables:** **~₹50 Cr** outstanding (resolving) ## B. Revenue Growth * **Resilient Top-Line:** 10% revenue growth achieved despite adverse conditions in key markets, indicating durable demand and operational resilience. ## C. Gross Margin * **Margin Pressure with Positive Trajectory:** Gross margins currently subdued due to Global Ingredients headwinds and operating inefficiencies, but **like-for-like improvement** evident in core business. * **Recovery Pathway Clear:** Margin stabilization underway, with **India factory ramp-up** expected to reduce logistics costs and restore efficient operations, driving sequential improvement. ## D. EBITDA Margin * **Adjusted Margin Visibility:** Underlying EBITDA margin of 13% reflects investment phase costs; management targets **17% in 2 years** as new capacities contribute. ## E. Balance Sheet * **Debt to Peak Near-Term:** Leverage expected to rise by **~₹100 Cr** due to expansion, but cash flow focus and **working capital optimization** are central to deleveraging strategy. * **GST Refund Resolution:** Refund inflows have resumed monthly/fortnightly, with **₹50 Cr backlog** expected to normalize within **3–6 months**, providing near-term liquidity relief. --- # 2. Capacity & Expansion ## A. Key Figures * **India Capacity:** **20,000 tons** current · **+9,000 tons** expansion (Q1 next FY) · **+15,000 tons** thereafter * **Southeast Asia Capacity:** **+3,600 tons** added, expected to generate **₹5–7 Cr** in sales * **Europe Utilization:** **90%** current utilization, targeting **2x capacity** by year-end/early next quarter * **New Facility Costs:** **€2.5 Mn** additional costs for new European centres * U.S. Investment: Prior investment of **$1.5–2 Mn** in Development Centre **B. S. Investment:** Prior investment of **$2–5 Mn** in Development Centre ## B. India Capacity * **Full Utilization & Expansion:** Both Indian facilities operating at full capacity with **no constraints**, supporting robust growth outlook through FY '27–'28. * **Cost-Efficient Relocation:** New facility launch in Q1 will replace older Mumbai unit, driving **operating cost savings** from lower lease expenses. * **Phased Ramp-Up:** Fire-affected factory migration set for Q4 next year or Q1 following, aligning with broader capacity transition. ## C. Europe Facility * **Global Competitiveness Push:** Strategic investments in U.K., Germany, U.S., UAE, and India target leadership in **~75% of global fragrance market**. * **Near-Term Operational Shift:** New European facility to go live by March (Q4), with full ramp-up by Q2–Q3 and complete transition from legacy sites by end-Q3 next year. * **Capacity Doubling Plan:** Europe’s installed base to **double capacity** amid strong utilization, enabling near-term volume growth. * **Controlled Cost Integration:** New initiatives incurred €5 Mn in costs; current all-in cost level expected to stabilize with minimal staffing changes. ## D. U.S. Development Centre * **Strategic Market Entry:** U.S. Creative Development Centre secured **first customer order**, marking entry into world’s largest F&F market. * **Integrated Innovation Hub:** Centre now part of global delivery framework, serving regional and multinational clients with **encouraging engagement**. * **Long-Term Organic Build:** U.S. platform expected to mature over **2–3 years**, with scalable benefits accruing progressively. ## E. Southeast Asia Output * **Organic Growth Focus:** Expansion in Southeast Asia, Americas, U.K., and Germany replaces prior M&A approach, emphasizing capital discipline. * **New Regional Scale:** Additional 3,600 tons of capacity established, positioning for **₹5–7 Cr in incremental sales** from the region. --- # 3. Product & Segment Performance ## A. Key Figures * **ROW Fragrances Revenue:** **₹282 Cr** (9 months) (from ₹215 Cr) * **EBITDA Margins:** 14–17% projected (Fragrances) * **Proprietary Products:** **85%** of product portfolio * **Patents:** **>25** global patents · **B. S. patents expire 2030** ## B. Flavours Business * **Stable Core Business:** Flavours segment in India has reached a mature, steady state with **sustained high-margin profile** (20–22% EBIT), supported by prior capex. * **Limited Near-Term Expansion:** Geographic expansion into Southeast Asia, Middle East, or Europe deferred until Fragrance investments show returns. ## C. Fragrances Segment * **Growth Momentum Abroad:** ROW Fragrances delivered strong revenue growth, reflecting early success in international markets. * **Investment Phase Continues:** Indian Fragrances EBIT margins currently depressed (~8%) due to ongoing overseas investments; international operations expected to stabilize in 2–4 years. * **Long-Term Margin Roadmap:** Clear path to **17–18% blended EBIT margin** in global Fragrances as scale and operating leverage improve. * **Favorable Market Dynamics:** Surge in niche, digitally-native brands is fueling a “fragrance springtime,” creating new client acquisition opportunities. ## D. Proprietary Products & Innovation * **Innovation-Driven Growth Engine:** Creation Development Centres (CDCs) are central to new business generation, acting as primary growth catalysts. * **Pricing Power Advantage:** High proprietary content (85%) enables effective cost pass-through and margin resilience. * **Sustainable IP Edge:** Robust patent portfolio (>25 patents) and innovation infrastructure underpin global competitiveness; **2030 U.S. patent expiry** sets a 5–7 year strategic window for technology-led growth. --- # 4. Customer & Market Reach ## A. Key Figures * **European Revenue:** **€45–50 Mn** projected for current year * European Business Growth: 3% YoY in euro terms (YoY) ## B. U.S. Client Orders * **On-Track U.S. Entry:** First orders secured and execution scheduled for **Q4 this year and Q1 next**, validating 18-month market entry strategy. * **India Demand Lags:** Domestic growth slower than expected despite **strong market position**, with recovery anticipated in near term. ## C. Europe Demand * **Resilient Core Demand:** Underlying traction with existing and new customers persists, though near-term performance softened by **geopolitical headwinds and tariffs**, leading to a de facto **11-month business year**. * **Cautious Trade Optimism:** Recent India-EU, U.K., and U.S. trade deals seen as positive, but company-specific benefits await detailed analysis. * **Stable Regional Growth:** European business shows **low single-digit growth in local currency**, indicating stability amid challenging conditions. ## D. ROW Revenue * **High-Growth Emerging Markets:** **Strong double-digit growth** observed in Middle East, Africa, and Central Asia, enhancing global diversification. * **International Expansion Paying Off:** Early success in new markets, including first U.S. order, expected to drive **future EBITDA improvement**. ## E. New Brand Pipeline * **Acquisition Resilience:** Business continuity maintained with clients acquired by major players like **Marico and Unilever**, reducing churn risk. * **Start-up Supplier Gap:** Fragmented supply base among emerging brands creates **white-space opportunity** for the company to gain share. * **New Brand Momentum:** While client stickiness remains high, rising number of new FMCG brands provides strategic avenue for customer acquisition. --- # 5. Capital Allocation & Capex ## A. Key Figures * **Capex (12–18 months):** **₹110–120 Cr** (India: ₹80 Cr; Europe: ₹25–30 Cr) * **Vashivali Facility Investment:** **₹70–80 Cr** (next 12–18 months) * **Additional Facility Outlay:** **₹30–40 Cr** (expected next fiscal) * **Insurance Proceeds:** **₹100 Cr** expected in 6–12 months * **Lease Cost Savings:** **₹3–4 Cr/year** from Mulund facility closure ## B. India Investment * **Strategic Capital Deployment:** Focus on disciplined investment in **capex, acquisitions, and R&D** to strengthen competitive positioning and drive long-term value. * **Rebuilding Momentum:** Vashivali facility reconstruction underway with capex front-loaded; insurance claim expected to offset a significant portion of costs. * **Promoter Engagement:** Management open to **promoter investment** amid market cap decline, reflecting confidence in current valuation and strategic direction. * **Financial Lessons Learned:** Hindsight indicates **staggered investments** could have reduced financial strain, suggesting more phased execution in future. ## C. Europe Outlay * **Europe Commitment Largely Executed:** **EUR 7–8 Cr** committed, with majority of capex already completed; limited near-term outflows expected. * **Near-Term Outflow:** **EUR 2–3 Mn** (₹25–30 Cr) expected from India in next 6–12 months for European projects. ## D. Hurdle Rate Target * **Rigorous Investment Criteria:** Targets **20% hurdle rate** and **20% ROI/ROCE within 3 years** for capital allocation decisions. --- # 6. Risks & Execution Challenges ## A. Key Figures * **Insurance Claim Expected:** **~₹100 Cr** (±) (6–12 months) * Insurance Premium Increase: ₹13–13.5 Cr annual run-rate above normal * **Employee Costs:** **₹93 Cr** this quarter (from ₹85 Cr) ## B. Insurance Timing * **Progress Amid Uncertainty:** Insurance claim resolution advancing faster than peers, with first claim processed despite typical 18–20 month timelines; full recovery of **pending receivables** remains subject to timing risks. * **Near-Term Cost Pressure:** Elevated insurance premiums to persist for **~one more year**, reflecting post-incident repricing. ## C. Currency Impact * **Margin Headwinds:** Gross margins pressured by adverse currency dynamics, as dollar prices declined faster than rupee costs for INR-denominated operations. * **Stable Opex in USD/EUR Terms:** Peak opex for development initiatives reached; underlying dollar-euro spending stable within **±2–3%**, though INR reporting may fluctuate. ## D. Fire Aftermath * **Capital Strain from Dual Shocks:** Financial pressure stems from confluence of major expansion capex and fire-related cash outflows, now impacting debt-to-equity management. * **Collateral Dynamics:** Share pledge of 10 lakh shares linked to existing loan covenants and market decline; potential for reversal upon price recovery. ## E. Labour Costs * **Cost Inflation from Structural Shifts:** Employee costs rose due to headcount growth, FX impact, and **true-up under New Labour Code**, with further increases expected until recent investments stabilize. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue CAGR Guidance:** **12%** medium-term target (from FY '24–'25 base) · **~11%** expected for current year * **EBITDA Margin Target:** Path to **17%** within two years * **ROCE Outlook:** **~14%** expected in 2–3 years · **Mid-teens** by FY '28–'29 ## B. Revenue CAGR * **Growth Resilience:** Medium-term **12% CAGR** remains intact despite near-term headwinds, supported by green shoots in FMCG and global outreach to small/mid-sized clients. * **Regional Momentum:** Strong growth expected in **Middle East and Southeast Asia**, with full-year target appearing challenging but long-term trajectory on track. * **Base Effect Dynamics:** Current year growth at **~11%** partly reflects low base in Q1, with acceleration anticipated over next 2–3 years. ## C. Margin Recovery * **Gross Margin Inflection:** Improvement expected from Jan–Mar quarter, with stronger recovery from April as high-cost inventory is fully absorbed. * **Cost Environment Stabilizing:** Raw material pressures easing, though **geopolitical and currency risks** remain key overhangs on margin trajectory. * **Progressive Margin Expansion:** Management affirms trend of **improving gross margins across segments**, driven by operating leverage and cycle recovery, though **45% gross margin not confirmed**. ## D. ROCE Trajectory * **ROCE Under Pressure:** Current levels in **single digits** due to timing of capex, with normalization expected as projects mature and new initiatives reach cash break-even. * **Long-Term ROCE Target:** Clear path to **mid-teens by FY '28–'29**, supported by upcoming capital allocation plan within 4–6 weeks. ## E. Growth Timeline * **Strategic Foundation Set:** New leadership confirms organizational alignment, with current investments laying groundwork for next-phase growth in global Fragrances & Flavours. * **Gestation Periods Ahead:** Major initiatives, including entry into markets **10x–12x larger** than current scale, entail extended ramp-up times; near-term performance to remain range-bound for **3–6 months**.